Treatment of Alzheimer's Disease with a Cholinesterase Inhibitor Combined with Antioxidants

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 193-202

  Cornelli, Umberto ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Alzheimer's disease; d ROMs test; Glutathione; Homocysteine; Sickle erythrocytes

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CARNOSINE; CHOLINESTERASE INHIBITOR; COGITON; CYANOCOBALAMIN; CYSTEINE; DONEPEZIL; FORMULA F; GLUTATHIONE; HOMOCYSTEINE; NICOTINAMIDE; PYRIDOXINE; RIBOFLAVIN; SELENIUM; THIAMINE; UBIDECARENONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CONFERENCE PAPER; DRUG EFFECT; DRUG FORMULATION; FEMALE; GINKGO BILOBA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PRIORITY JOURNAL; SICKLE CELL; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIOXIDANTS; BISPHENOL A-GLYCIDYL METHACRYLATE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HOMOCYSTEINE; HUMANS; INDANS; MALE; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PIPERIDINES; POLYURETHANES; PROTEOGLYCANS; REACTIVE OXYGEN SPECIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953561035     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000295663     Document Type: Conference Paper

References (78)

1. Ding Q, Dimayuga E, Keller JN: Oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease. Curr Alzheimer Res 2007; 4: 73-79.
2. Dröge W, Schipper MH: Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 2007; 6: 361-370.
3. Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71: 621S- 629S.
4. Smith MA, Vasak K, Knipp M, et al: Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer's disease. Free Radic Biol Med 1998; 25: 898-902.
5. Luth HJ, Munch G, Gartner U, et al: Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesions in rats: evidence for an induction by amyloid pathology. Brain Res 2001; 913: 57-67.
6. Heneka MT, Wiesinger H, Dumitrescu- Ozimek L, et al: Neuronal and glial coexpression of arginosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 906-916.
7. Lee SC, Zhao ML, Hirano A, Dickson DW: Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol 199; 58: 1163-1169.
8. Soneja A, Drews M, Malinski T: Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmac Report 2005; 57: 108-119.
9. Malinski T: Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis 2007; 11: 207-218.
10. Hawkins BT, Davis T: The blood-brain barrier/ neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-185.
11. Stewart PA, Hayakawa K, Akers MA, Vinters HV: A morphometric study of the bloodbrain barrier in Alzheimer's disease. Lab Invest 1992; 67: 734-742.
12. Andreyev AY, Kushnareva YE, Starkov AA: Mitochondrial metabolism of reactive species. Biochemistry (Moscow) 2005; 70: 200-214.
13. Wang J, Xiong S, Xie C, et al: Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 2005; 93: 933-962.
14. Lin MT, Beal MF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 433: 787-795.
15. Sas K, Robotka H, Toldi J, Vécsei L: Mitochondria, metabolic disturbances, oxidative stress and kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007; 257: 221-239.
16. Marlatt M, Lee H, Perry G, et al: Sources and mechanism of cytoplasmatic oxidative damage in Alzheimer's disease. Acta Neurobiol Exp 2004; 64: 81-87. (Pubitemid 38453808)
17. Hirai K, Aliev G, Nunomura A, et al: Mitochondrial abnormalities in Alzheimers disease. J Neurosci 2001; 21: 3017-3023.
18. Mecocci P, Polidori MC, Cherubini A, et al: Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 2002; 59: 794-798.
19. Blass JP, Gibson GE: The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev Neurol (Paris) 1991; 147: 513-525.
20. Zhu X, Smith MA, Honda K, et al: Vascular oxidative stress in Alzheimers disease. J Neurol Sci 2007; 257: 240-246. (Pubitemid 46856513)
21. Hachinski V, Munoz DG: Cerebrovascular pathology in Alzheimer's disease: cause, effect or epiphenomenon? Ann NY Acad Sci 1997; 826: 1-6. (Pubitemid 27478026)
22. Babiloni C, Bosco P, Ghidoni R, et al: Homocysteine and electroencephalographic rhythms in Alzheimer disease: a multicentric study. Neuroscience 2007; 143: 942-954.
23. Seshadri S, Beiser A, Selhub J, et al: Plasma HCy as risk factor for dementia and Alzheimer's disease. NEJM 2002; 346: 476-483.
24. Ravaglia G, Forti P, Maioli F, et al: HCy and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005; 82: 636-643.
25. Bleie Ø, Refsum H, Ueland PM, et al: Changes in basal and postmethionine load concentration of total HCy and cystationine after B vitamin intervention. Am J Clin Nutr 2004; 80: 641-648.
26. Lee BJ, Huang MC, Chung LJ, et al: Folic acid and vitamin B 12 are more effective than vitamin B 6 in lowering fasting plasma homocysteine concentration in patients with coronary artery disease. Eur J Clin Nutr 2004; 58: 481-487.
27. NcKinley MC, McNulty H, McPartlin J, et al: Low-dose vitamin B 6 effectively lowers fasting HCy in healthy elderly person who are folate and riboflavin replete. Am J Clin Nutr 2001; 73: 759-764.
28. Bønaa KH, Njølstad NJ, Ueland PM, et al: Homocysteine lowering and cardiovascular events after acute myocardial infarction. NEJM 2006; 354: 1578-1588.
29. Ebbing M, Bleie Ø, Ueland PM, et al: Mortality cardiovascular events in patients treated with HCy-lowering B vitamin after coronary angiography: a randomized clinical trial. JAMA 2008; 300: 795-804.
30. Selkoe DJ: Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994; 17: 489-517.
31. Näslund J, Haroutonian V, Mohs R, et al: Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-1577.
32. Butterfield DA: Amyloid beta-peptide (1- 42)-induced oxidative stress and neurotoxicity: implication for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 2002; 36: 1307-1313.
33. Kontush A: Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med 2001; 31: 1120-1131.
34. Suo Z, Su G, Kundtz A, et al: A beta vasoactivity in vivo. Ann NY Acad Sci 2000; 903: 156-163.
35. Guiotto A, Calderan A, Ruzza P, Borin G: Carnosine and carnosine-related antioxidants: a review. Curr Med Chem 2005; 12: 2293-2315.
36. Hipkiss AR: Could carnosine or related structures suppress Alzheimer's disease? J Alzheimers Dis 2007; 11: 229-240.
37. Cleary JP, Walsh DM, Hofmeister JJ, et al: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
38. Walsh DM, Selkoe DJ: Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004; 11: 213-228.
39. Alhamdani MSS: Impairment of glutathione biosynthetic pathway in uremia and dialysis. Nephrol Dial Transplant 2005; 20: 124-128.
40. Reid M, Badaloo A, Forrester T, Jahoor F: In vivo rates of erythrocytes glutathione synthesis in adults with sickle cell disease. Am J Physiol Endocrinol Metab 2006; 291:E73-E79.
41. Mohanty JG, Eckley DM, Williamson JD, et al: Do red blood cell-β-amyloid interaction alter oxygen delivery in Alzheimer's disease? Adv Exp Med Biol 2008; 614: 29-35.
42. Singer SJ, Dewji NN: Evidence that Perutz's double-β-stranded subunit structure for β- amyloid also applies to their channel-forming structures in membranes. PNAS 2006; 103: 1546-1550.
43. Engström I, Ronquist G, Petterson L, Waldenström A: Alzheimer amyloid betapeptides exhibit ionophore-like properties in human erythrocytes. Eur J Clin Invest 1995; 25: 471-476.
44. Ravi LB, Mohanty JG, Chrest FJ, et al: Influence of beta-amyloid fibrils on the interactions between red blood cells and endothelial cells. Neurol Res 2004; 26: 579-585.
45. Cornelli U: Glycosaminoglycans as potential future treatment of Alzheimer's disease; in Richter RW, Richter BZ (eds): Alzheimer's Disease. A Physician Guide to Practical Management. Totowa, Humana Press, 2004.
46. Van Vactor D, Wall DP, Johnson KG: Heparan sulphate proteoglycans and the emergence of neuronal connectivity. Curr Opin Neurobiol 2006; 16: 50-51.
47. Galtrey CM, Fawcett JW: The role of condroitin sulphate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res Rev 2007; 54: 1-18.
48. Metcalfe DD, Thompson HL, Klebanoff SJ, Henderson WR: Oxidative degradation of rat mast-cell proteoglycan. Biochem J 1990; 272: 51-57.
49. Roberts CR, Roughley PJ, Mort JS: Degradation of human proteoglycan aggregates induced by hydrogen peroxide. Biochem J 1989; 259: 805-811.
50. Wessjohann LA, Schneider A, Abbas M, Brandt W: Selenium in chemistry and biochemistry in comparison to sulfur. Biol Chem 2007; 388: 997-1006.
51. Wu G, Fang YZ, Yang S, et al: Glutathione metabolism and its implications for health. J Nutr 2004; 134: 489-492.
52. Franco R, Schoneveld OJ, Pappa A, Panayioditis MI: The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem 2007; 113: 234-258.
53. Littarru GP, Tiano L: Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 2007; 37: 31-37.
54. Koltermann A, Harkorn A, Koch E, et al: Ginkgo biloba extract Egb 761 increases endothelial nitric oxide production in vitro and vivo. Cell Mol Life Sci 2007; 64: 1715-1722.
55. Napryeyenko O, Borzenko I, GINDEM-NP Study Group: Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomized placebo-controlled doubleblind clinical trial. Arzneimittelforschung 2007; 57: 4-11.
56. Mazza M, Capuano A, Bria P, Mazza S: Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006; 13: 981-985.
57. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
58. Romàn GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: diagnostic criteria for research studies: report of the NINDSAIREN International Workshop. Neurology 1993; 43: 250-260.
59. Cesarone MR, Belcaro G, Carratelli M, et al: A simple test to monitor oxidative stress. Int Angiol 1999; 18: 127-130.
60. Cornelli U, Terranova R, Luca S, et al: Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr 2001; 131: 3208-3211.
61. Reid M, Badaloo A, Forrester T, Jahoor F: In vivo rates of erythrocyte glutathione synthesis in adults with sickle cell disease. Am J Physiol Endocrinol Metab 2006; 291:E73-E79.
62. Bleie Ø, Refsum H, Ueland PM, et al: Changes in basal and postmethionine load concentration of total homocysteine and cystationine after B vitamin intervention. Am J Clin Nutr 2004; 80: 641-648.
63. McDermott MM, Liu K, Ferrucci L, et al: Circulating markers and functional impairment in peripheral arterial disease. J Am Geriatr Soc 2008,56: 1504-1510.
64. Wang X, Qin X, Demitras H, et al: Efficacy of folic acid supplementation in stroke prevention: a meta analysis. Lancet 2007; 369: 1876-1882.
65. Potter K, Hankey GJ, Green DJ, et al: The effect of long term homocysteine-lowering on carotid intima-media thickness and flowmediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovasc Disord 2008; 8: 24.
66. Stanger O, Herrmann W, Pietrzik K, et al: DACH-LIGA Homocystein (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic disease: guidelines and recommendation. Clin Chem Lab Med 2003; 41: 1392-1403.
67. Yaffe K, Clemons TE, McBee WL, et al: Impact of antioxidants, zinc, and copper, on cognition in the elderly: a randomized clinical trial. Neurology 2004; 63: 1705-1707.
68. Gray SL, Anderson ML, Crane PK, et al: Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. J Am Geriatr Soc 2008;56: 291-295.
69. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al: Meta-analysis: high dosages vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
70. Aisen PS, Schneider LS, Sano M, et al: Highdose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008;300: 1774-1783.
71. Malouf M, Grimley EJ, Areosa SA: Folic acid with or without vitamin B 12 for cognition and dementia. Cochrane Database Syst Rev 2003;CD004514.
72. Ravaglia G, et al: Plasma tocopherol and risk of cognitive impairment in an elderly Italian cohort. Am J Clin Nutr 2008; 87: 1306-1313.
73. Ringman JM: Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer's disease. Evid Based Ment Health 2006; 9: 104-117.
74. Setzer B: Donepezil an update. Expert Opin Pharmacother 2007: 8:1011-1023.
75. Petersen RC, Thomas RG, Grundman M, et al: Vitamin E and donepezil for the treatment of mild cognitive impairment. NEJM 2005; 352: 2379-2388.
76. Montine TJ, Montine KF, McMahan W, et al: F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antiox Redox Signal 2005; 7: 269-275.
77. Montine TJ, Quinn J, Kaie J, Morrow JD: F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci 2007; 33: 114-119.
78. Pogribna M, Melnik S, Pogribni I, Chango P, et al: HCy metabolism with Down syndrome: in vitro stimulation. Am J Hum Genet 2001; 69: 88-95.